BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 28630044)

  • 21. Restoration of topoisomerase 2 function by complementation of defective monomers in Drosophila.
    Hohl AM; Thompson M; Soshnev AA; Wu J; Morris J; Hsieh TS; Wu CT; Geyer PK
    Genetics; 2012 Nov; 192(3):843-56. PubMed ID: 22923380
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Broken by the Cut: A Journey into the Role of Topoisomerase II in DNA Fragility.
    Atkin ND; Raimer HM; Wang YH
    Genes (Basel); 2019 Oct; 10(10):. PubMed ID: 31614754
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of antineoplastic drugs on the post-strand-passage DNA cleavage/religation equilibrium of topoisomerase II.
    Robinson MJ; Osheroff N
    Biochemistry; 1991 Feb; 30(7):1807-13. PubMed ID: 1847075
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Eukaryotic topoisomerase II. Characterization of enzyme turnover.
    Osheroff N
    J Biol Chem; 1986 Jul; 261(21):9944-50. PubMed ID: 3015913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Unlocking and opening a DNA gate.
    Wang JC
    Proc Natl Acad Sci U S A; 2007 Mar; 104(12):4773-4. PubMed ID: 17363472
    [No Abstract]   [Full Text] [Related]  

  • 26. Small Molecule Inhibitors Confirm Ubiquitin-Dependent Removal of TOP2-DNA Covalent Complexes.
    Swan RL; Poh LLK; Cowell IG; Austin CA
    Mol Pharmacol; 2020 Sep; 98(3):222-233. PubMed ID: 32587095
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A flow cytometry-based method for a high-throughput analysis of drug-stabilized topoisomerase II cleavage complexes in human cells.
    de Campos-Nebel M; Palmitelli M; González-Cid M
    Cytometry A; 2016 Sep; 89(9):852-60. PubMed ID: 27517472
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dynamics of strand passage catalyzed by topoisomerase II.
    Xie P
    Eur Biophys J; 2010 Jul; 39(8):1251-9. PubMed ID: 20127325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Molecular determinants of response to topoisomerase II inhibitors].
    Lansiaux A; Pourquier P
    Bull Cancer; 2011 Nov; 98(11):1299-310. PubMed ID: 22023806
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DNA topoisomerase II structures and anthracycline activity: insights into ternary complex formation.
    Dal Ben D; Palumbo M; Zagotto G; Capranico G; Moro S
    Curr Pharm Des; 2007; 13(27):2766-80. PubMed ID: 17897022
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interaction model for anthracycline activity against DNA topoisomerase II.
    Moro S; Beretta GL; Dal Ben D; Nitiss J; Palumbo M; Capranico G
    Biochemistry; 2004 Jun; 43(23):7503-13. PubMed ID: 15182192
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of TDP2 on the Level of TOP2-DNA Complexes and SUMOylated TOP2-DNA Complexes.
    Lee KC; Swan RL; Sondka Z; Padget K; Cowell IG; Austin CA
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30011940
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Type II DNA Topoisomerases Cause Spontaneous Double-Strand Breaks in Genomic DNA.
    Morimoto S; Tsuda M; Bunch H; Sasanuma H; Austin C; Takeda S
    Genes (Basel); 2019 Oct; 10(11):. PubMed ID: 31671674
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing.
    Deweese JE; Osheroff N
    Nucleic Acids Res; 2009 Feb; 37(3):738-48. PubMed ID: 19042970
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of bisdioxopiperazine dexrazoxane binding to human DNA topoisomerase II alpha: decreased binding as a mechanism of drug resistance.
    Renodon-Cornière A; Jensen LH; Nitiss JL; Jensen PB; Sehested M
    Biochemistry; 2003 Aug; 42(32):9749-54. PubMed ID: 12911317
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Eukaryotic DNA topoisomerases mediated DNA cleavage induced by a new inhibitor: NSC 665517.
    Gupta M; Abdel-Megeed M; Hoki Y; Kohlhagen G; Paull K; Pommier Y
    Mol Pharmacol; 1995 Oct; 48(4):658-65. PubMed ID: 7476891
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of topoisomerase II-targeted drugs on enzyme-mediated DNA cleavage and ATP hydrolysis: evidence for distinct drug interaction domains on topoisomerase II.
    Robinson MJ; Corbett AH; Osheroff N
    Biochemistry; 1993 Apr; 32(14):3638-43. PubMed ID: 8385484
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Direct measurement of DNA bending by type IIA topoisomerases: implications for non-equilibrium topology simplification.
    Hardin AH; Sarkar SK; Seol Y; Liou GF; Osheroff N; Neuman KC
    Nucleic Acids Res; 2011 Jul; 39(13):5729-43. PubMed ID: 21421557
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BRCA1 ensures genome integrity by eliminating estrogen-induced pathological topoisomerase II-DNA complexes.
    Sasanuma H; Tsuda M; Morimoto S; Saha LK; Rahman MM; Kiyooka Y; Fujiike H; Cherniack AD; Itou J; Callen Moreu E; Toi M; Nakada S; Tanaka H; Tsutsui K; Yamada S; Nussenzweig A; Takeda S
    Proc Natl Acad Sci U S A; 2018 Nov; 115(45):E10642-E10651. PubMed ID: 30352856
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The top2-5 mutant of yeast topoisomerase II encodes an enzyme resistant to etoposide and amsacrine.
    Jannatipour M; Liu YX; Nitiss JL
    J Biol Chem; 1993 Sep; 268(25):18586-92. PubMed ID: 8395511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.